David Johnson Einstein, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Prostatic Neoplasms | 14 | 2024 | 11101 | 1.410 |
Why?
|
Carcinoma, Renal Cell | 6 | 2024 | 3187 | 0.890 |
Why?
|
Kidney Neoplasms | 5 | 2024 | 4282 | 0.850 |
Why?
|
Androgen Receptor Antagonists | 2 | 2024 | 123 | 0.820 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 2 | 2024 | 1105 | 0.730 |
Why?
|
Terminal Care | 5 | 2017 | 1770 | 0.690 |
Why?
|
Urogenital Neoplasms | 1 | 2020 | 130 | 0.650 |
Why?
|
Receptors, Androgen | 3 | 2023 | 1089 | 0.640 |
Why?
|
Phenylurea Compounds | 1 | 2022 | 531 | 0.630 |
Why?
|
Androstenes | 2 | 2019 | 177 | 0.630 |
Why?
|
Compassionate Use Trials | 1 | 2018 | 50 | 0.620 |
Why?
|
Androgen Antagonists | 3 | 2024 | 1412 | 0.610 |
Why?
|
Neoplasm Recurrence, Local | 6 | 2024 | 9419 | 0.600 |
Why?
|
Quinolines | 1 | 2022 | 772 | 0.540 |
Why?
|
Paternalism | 1 | 2016 | 49 | 0.530 |
Why?
|
Tumor Microenvironment | 3 | 2024 | 3948 | 0.510 |
Why?
|
Carcinoma, Transitional Cell | 2 | 2021 | 794 | 0.510 |
Why?
|
Death | 2 | 2017 | 683 | 0.500 |
Why?
|
Telephone | 1 | 2019 | 630 | 0.490 |
Why?
|
Advance Directives | 1 | 2016 | 249 | 0.460 |
Why?
|
Immunotherapy, Adoptive | 1 | 2024 | 1512 | 0.450 |
Why?
|
Empathy | 1 | 2018 | 474 | 0.440 |
Why?
|
Physician-Patient Relations | 5 | 2022 | 3269 | 0.440 |
Why?
|
Personal Autonomy | 1 | 2016 | 315 | 0.430 |
Why?
|
Cisplatin | 1 | 2019 | 1660 | 0.410 |
Why?
|
CD8-Positive T-Lymphocytes | 3 | 2024 | 4648 | 0.390 |
Why?
|
Facial Paralysis | 1 | 2015 | 346 | 0.370 |
Why?
|
Vascular Endothelial Growth Factor A | 2 | 2022 | 3517 | 0.350 |
Why?
|
Urinary Bladder Neoplasms | 2 | 2021 | 2195 | 0.340 |
Why?
|
Sarcoidosis | 1 | 2015 | 535 | 0.330 |
Why?
|
Quality of Life | 2 | 2023 | 13490 | 0.320 |
Why?
|
Immunotherapy | 4 | 2021 | 4754 | 0.310 |
Why?
|
Internal Medicine | 1 | 2015 | 1064 | 0.290 |
Why?
|
Prostatectomy | 4 | 2024 | 1786 | 0.280 |
Why?
|
Cardiopulmonary Resuscitation | 1 | 2015 | 997 | 0.280 |
Why?
|
Prostate-Specific Antigen | 4 | 2024 | 2463 | 0.280 |
Why?
|
Neoplasms | 6 | 2022 | 22371 | 0.280 |
Why?
|
Internet | 1 | 2019 | 3110 | 0.270 |
Why?
|
Palliative Care | 2 | 2021 | 3643 | 0.260 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2020 | 5341 | 0.250 |
Why?
|
Medical Oncology | 1 | 2017 | 2346 | 0.240 |
Why?
|
Decision Making | 2 | 2016 | 3953 | 0.240 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2024 | 3612 | 0.220 |
Why?
|
Leuprolide | 2 | 2024 | 313 | 0.210 |
Why?
|
Antineoplastic Agents | 3 | 2023 | 13677 | 0.210 |
Why?
|
Chromosomes, Human, X | 1 | 2024 | 320 | 0.200 |
Why?
|
Radium | 1 | 2023 | 70 | 0.200 |
Why?
|
Receptor Tyrosine Kinase-like Orphan Receptors | 1 | 2022 | 43 | 0.200 |
Why?
|
Humans | 39 | 2024 | 768171 | 0.200 |
Why?
|
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2024 | 325 | 0.190 |
Why?
|
Male | 24 | 2024 | 364731 | 0.190 |
Why?
|
Thiohydantoins | 1 | 2021 | 19 | 0.190 |
Why?
|
Attitude of Health Personnel | 1 | 2015 | 3929 | 0.180 |
Why?
|
Phenylthiohydantoin | 2 | 2019 | 207 | 0.180 |
Why?
|
Prednisone | 2 | 2024 | 1567 | 0.170 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 2022 | 662 | 0.160 |
Why?
|
Translocation, Genetic | 1 | 2024 | 1394 | 0.150 |
Why?
|
Cryosurgery | 1 | 2023 | 479 | 0.150 |
Why?
|
Sickness Impact Profile | 1 | 2019 | 299 | 0.150 |
Why?
|
Neutropenia | 1 | 2023 | 892 | 0.140 |
Why?
|
Morbidity | 1 | 2023 | 1755 | 0.140 |
Why?
|
Nitriles | 2 | 2019 | 980 | 0.140 |
Why?
|
Forkhead Transcription Factors | 1 | 2024 | 1625 | 0.140 |
Why?
|
Urothelium | 1 | 2019 | 275 | 0.140 |
Why?
|
Genes, Tumor Suppressor | 1 | 2021 | 1062 | 0.140 |
Why?
|
Benzamides | 2 | 2019 | 1379 | 0.140 |
Why?
|
Disease-Free Survival | 2 | 2024 | 6847 | 0.130 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2024 | 2459 | 0.130 |
Why?
|
Erythema Nodosum | 1 | 2015 | 32 | 0.120 |
Why?
|
Drug Approval | 1 | 2022 | 821 | 0.120 |
Why?
|
Internship and Residency | 1 | 2015 | 5953 | 0.120 |
Why?
|
Serine | 1 | 2018 | 831 | 0.120 |
Why?
|
Soft Tissue Neoplasms | 1 | 2023 | 1164 | 0.110 |
Why?
|
Phylogeny | 1 | 2021 | 2843 | 0.110 |
Why?
|
Cell Cycle Proteins | 1 | 2024 | 3445 | 0.110 |
Why?
|
Renal Insufficiency | 1 | 2019 | 812 | 0.100 |
Why?
|
Anecdotes as Topic | 1 | 2012 | 56 | 0.100 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2021 | 1536 | 0.100 |
Why?
|
Angiogenesis Inhibitors | 1 | 2022 | 2057 | 0.100 |
Why?
|
Proto-Oncogene Proteins | 1 | 2024 | 4528 | 0.100 |
Why?
|
Sarcoma | 1 | 2023 | 1806 | 0.100 |
Why?
|
Ambulatory Care Facilities | 1 | 2017 | 939 | 0.090 |
Why?
|
Professional-Patient Relations | 1 | 2016 | 724 | 0.090 |
Why?
|
Neoplasm Invasiveness | 1 | 2019 | 3620 | 0.090 |
Why?
|
Hospice Care | 1 | 2017 | 678 | 0.090 |
Why?
|
Survival Analysis | 2 | 2020 | 10099 | 0.080 |
Why?
|
Biopsy | 1 | 2021 | 6792 | 0.080 |
Why?
|
Prognosis | 3 | 2020 | 30009 | 0.080 |
Why?
|
Virus Diseases | 1 | 2015 | 724 | 0.080 |
Why?
|
Culture | 1 | 2012 | 622 | 0.080 |
Why?
|
Aged | 7 | 2024 | 171502 | 0.070 |
Why?
|
Molecular Targeted Therapy | 1 | 2019 | 2830 | 0.070 |
Why?
|
Positron-Emission Tomography | 1 | 2024 | 6669 | 0.070 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2020 | 8648 | 0.070 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2024 | 10397 | 0.070 |
Why?
|
Neovascularization, Pathologic | 1 | 2017 | 2631 | 0.070 |
Why?
|
Disease Progression | 1 | 2024 | 13668 | 0.070 |
Why?
|
Risk Assessment | 4 | 2021 | 24318 | 0.070 |
Why?
|
Androgens | 2 | 2024 | 1281 | 0.060 |
Why?
|
Prevalence | 1 | 2023 | 15869 | 0.060 |
Why?
|
Melanoma | 1 | 2024 | 5706 | 0.060 |
Why?
|
Middle Aged | 6 | 2024 | 223487 | 0.060 |
Why?
|
Pteridines | 1 | 2024 | 47 | 0.060 |
Why?
|
Cross-Sectional Studies | 2 | 2023 | 26379 | 0.060 |
Why?
|
Neoplasm Staging | 1 | 2019 | 11244 | 0.060 |
Why?
|
Phenotype | 1 | 2021 | 16726 | 0.050 |
Why?
|
Clinical Trials as Topic | 1 | 2019 | 8052 | 0.050 |
Why?
|
Longitudinal Studies | 1 | 2019 | 14783 | 0.050 |
Why?
|
Age Factors | 1 | 2019 | 18415 | 0.050 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2022 | 11878 | 0.050 |
Why?
|
Kidney | 1 | 2017 | 7064 | 0.050 |
Why?
|
Autocrine Communication | 1 | 2022 | 168 | 0.050 |
Why?
|
United States | 2 | 2022 | 73039 | 0.050 |
Why?
|
Female | 5 | 2024 | 397187 | 0.040 |
Why?
|
Drug Synergism | 1 | 2024 | 1760 | 0.040 |
Why?
|
Role | 1 | 2020 | 176 | 0.040 |
Why?
|
Diagnosis, Differential | 1 | 2015 | 13013 | 0.040 |
Why?
|
RNA, Double-Stranded | 1 | 2021 | 292 | 0.040 |
Why?
|
Combined Modality Therapy | 2 | 2021 | 8542 | 0.040 |
Why?
|
Treatment Outcome | 5 | 2024 | 65379 | 0.040 |
Why?
|
Preoperative Period | 1 | 2021 | 565 | 0.040 |
Why?
|
Haplotypes | 1 | 2024 | 2722 | 0.040 |
Why?
|
Mice, Inbred ICR | 1 | 2018 | 363 | 0.040 |
Why?
|
Physicians | 1 | 2016 | 4598 | 0.040 |
Why?
|
Prospective Studies | 2 | 2021 | 54924 | 0.040 |
Why?
|
Mitosis | 1 | 2023 | 1178 | 0.040 |
Why?
|
Interferons | 1 | 2021 | 720 | 0.030 |
Why?
|
beta Catenin | 1 | 2022 | 1047 | 0.030 |
Why?
|
Salvage Therapy | 1 | 2023 | 1273 | 0.030 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2024 | 1613 | 0.030 |
Why?
|
Cohort Studies | 1 | 2019 | 41753 | 0.030 |
Why?
|
Mutation | 1 | 2020 | 30237 | 0.030 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2020 | 757 | 0.030 |
Why?
|
Animals | 4 | 2024 | 169285 | 0.030 |
Why?
|
Cell Line, Tumor | 2 | 2024 | 17142 | 0.030 |
Why?
|
Perception | 1 | 2021 | 1209 | 0.030 |
Why?
|
Signal Transduction | 1 | 2017 | 23648 | 0.030 |
Why?
|
Sex Characteristics | 1 | 2024 | 2649 | 0.030 |
Why?
|
Piperazines | 1 | 2024 | 2554 | 0.030 |
Why?
|
Mice, SCID | 1 | 2018 | 2627 | 0.030 |
Why?
|
Testosterone | 1 | 2024 | 2491 | 0.030 |
Why?
|
Feasibility Studies | 1 | 2023 | 5315 | 0.030 |
Why?
|
Prostate | 1 | 2020 | 1765 | 0.020 |
Why?
|
Pyrimidines | 1 | 2024 | 3048 | 0.020 |
Why?
|
Immunologic Factors | 1 | 2021 | 1596 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2021 | 6316 | 0.020 |
Why?
|
Neoadjuvant Therapy | 1 | 2021 | 2907 | 0.020 |
Why?
|
Health Status Disparities | 1 | 2020 | 1885 | 0.020 |
Why?
|
Cell Proliferation | 1 | 2024 | 10478 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 2 | 2023 | 20762 | 0.020 |
Why?
|
Patient Selection | 1 | 2020 | 4260 | 0.020 |
Why?
|
Apoptosis | 1 | 2024 | 9527 | 0.020 |
Why?
|
Protein Kinase Inhibitors | 1 | 2024 | 5704 | 0.020 |
Why?
|
Phosphorylation | 1 | 2018 | 8316 | 0.020 |
Why?
|
Mice | 2 | 2024 | 82049 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2018 | 11095 | 0.010 |
Why?
|
Genomics | 1 | 2020 | 5926 | 0.010 |
Why?
|
Adult | 1 | 2015 | 223646 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2020 | 39354 | 0.010 |
Why?
|
Retrospective Studies | 1 | 2023 | 81760 | 0.010 |
Why?
|